Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO

Aspire Biopharma Holdings, Inc.

Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.
Board appointed Michael C. Howe, previously an independent board member, as CEO effective June 10, 2025.
Howe led MinuteClinic from 19 clinics to sale to CVS in 2006, delivering nearly sixfold return for investors.
Howe has 40+ years experience at Procter & Gamble, PepsiCo, Arby's (CEO), and early-stage healthcare companies.
Press release issued June 10, 2025, detailing leadership transition and Howe's background.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Howe

Chief Executive Officer

ASBP · Aspire Biopharma Holdings, Inc.

Effective: 2025-06-10
Filed: Jun 10, 2025 23:59 UTC

the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.

Departed

Kraig Higginson

Chief Executive Officer

ASBP · Aspire Biopharma Holdings, Inc.

Effective: 2025-06-10
Successor: Michael Howe
Filed: Jun 10, 2025 23:59 UTC

On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.

Source: SEC EDGAR

accession 0001641172-25-014445

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.